<DOC>
	<DOCNO>NCT00991068</DOCNO>
	<brief_summary>The purpose study explore potential usefulness Synera treatment pain associate mild moderate carpal tunnel syndrome .</brief_summary>
	<brief_title>Open-Label Study Evaluating Synera® Treatment Patients With Carpal Tunnel Syndrome</brief_title>
	<detailed_description>ZARS Pharma , Inc. develop Synera® ( lidocaine 70 mg tetracaine 70 mg topical patch ) , drug delivery patch utilize control heat enhance delivery local anesthetic formulation consist eutectic mixture lidocaine tetracaine . Synera approve Food Drug Administration ( FDA ) June 23 , 2005 indicate use intact skin provide local dermal analgesia superficial venous access superficial dermatological procedure excision , electrodesiccation , shave biopsy skin lesion . The purpose single center , 2-week open-label pilot study explore potential usefulness Synera treatment pain associate mild moderate CTS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carpal Tunnel Syndrome</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Tetracaine</mesh_term>
	<criteria>Pain associate mild moderate carpal tunnel syndrome single wrist Have recent ( within 3 month ) electrodiagnostic evidence carpal tunnel syndrome ( CTS ) Have bilateral carpal tunnel syndrome Have another peripheral neuropathy affect limb Have injection carpal tunnel within 8 week Have surgical release target wrist within previous 6 month Have electrodiagnostic evidence severe CTS Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pain</keyword>
	<keyword>Mild moderate Carpal Tunnel Syndrome</keyword>
</DOC>